Dr. Julian Rees co-founded HOPO Therapeutics and has led the company as President and Chief Executive Officer since 2020. He has spent over 15 years studying the interactions between metal ions and biological systems, with foci in biological inorganic chemistry, ligand and chelator design, and heavy metal decorporation. Julian has authored and designed multiple research studies detailing critical investigations of the efficacy and applications of HOPO’s lead drug candidate, as well as developed new appplications and technologies in nuclear medicine.

Julian received a B.A. in Chemistry from Goucher College, earned his M.S. and Ph.D. in Chemistry from the University of Washington, and has held research fellowships at the Max Planck Institute for Chemical Energy Conversion, the University of California, Berkeley, and Lawrence Berkeley National Laboratory. Julian is currently an Activate Fellow at Berkeley Lab’s Cyclotron Road.

Back